哈药牌品牌怎么样 申请店铺

我要投票 哈药牌在补铁锌硒行业中的票数:564 更新时间:2025-08-02
哈药牌是哪个国家的品牌?「哈药牌」是 哈药集团有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人张利君在1989期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力哈药牌品牌出海!将品牌入驻外推网,定制哈药牌品牌推广信息,可以显著提高哈药牌产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

哈药牌怎么样

哈药集团制药总厂始建于1958年,经过半个世纪的艰苦创业,不懈追求,已经由名不见经传的简陋小厂发展成为国内拥有先进理念、科学管理、核心竞争力的大型综合性制药企业,位列全国医药“百强”企业之首。年销售收入近50亿元,出口创汇1亿多美元。

公司主要生产青霉素类、头孢菌素类、大环内酯类抗生素以及心脑血管用药等30种原料药、原料中间体和100多种制剂品种。青霉素工业盐和7ACA两大母核的技术质量指标始终处于国内领先、国际一流水平。

企业拥有技术装备先进、管理体系完善的科研开发中心、质量检验中心、计控中心及生产、销售、服务等系统和职能部门,拥有精干、专业、严谨、高效的管理团队和敬业、忠诚、团结、向上的员工队伍。

企业先后自行研制开发了三类新药凯兰欣、铃兰欣、头孢吡肟、头孢替唑等,四类新药头孢唑肟钠、盐酸头孢替安、、盐酸头孢他美酯等几十种新产品。头孢替安无菌原料药是国内独家品种,获得了省科技进步奖、国家重点新稆证书;头孢美唑工艺技术的攻关成果获得国家重点新产品证书和医药行业科技进步一等奖。

企业的主导产品青霉素、头孢菌素类原粉和制剂均通过国家药品监督管理局GMP认证;青霉素工业钾盐通过了美国FDA认证;部分原料药和制剂通过南非卫生部的GMP认证;头孢唑林钠、头孢曲松钠原料药通过欧洲EDMF认证。

哈药集团制药总厂是中国重点抗生素生产和出口基地。营销系统下设九个销售公司,在全国29个省分布有62个办事处、600余名销售业务员,拥有5600多个经销商,产品覆盖除港澳台以外的所有区县。国际贸易营销网络覆盖中东、东南亚、南美、印度、俄罗斯以及原独联体其它国家、非洲、欧盟等市场,产品远销40多个国家和地区。

“哈药”品牌在2010年中国最有价值的品牌评价中,价值已达到160.62亿元,成为中国医药行业之冠和黑龙江省第一品牌。哈药集团制药总厂是国家级重合同守信用单位,哈药产品以优质、高效、安全在广大客户和消费者心目中享有盛誉。

哈药集团制药总厂秉承“厚德载物、兢兢以强”的企业精神,始终以发展和壮大祖国医药事业、造福人类健康为已任,孜孜以求,矢志超越,全力打造中国最具科技实力、经营潜力、发展张力、文化魅力的规范化、现代化、国际化的医药界强企,努力为社会、为人类创造更大的价值。

Harbin Pharmaceutical Group Pharmaceutical General Factory was founded in 1958. After half a century of hard work and unremitting pursuit, it has developed from a humble small factory to a large comprehensive pharmaceutical enterprise with advanced concept, scientific management and core competitiveness, ranking first among the "top 100" pharmaceutical enterprises in China. The annual sales revenue is nearly 5 billion yuan, and the export income is more than 100 million US dollars. The company mainly produces 30 kinds of APIs, raw material intermediates and more than 100 kinds of preparation varieties, such as penicillin, cephalosporins, macrolides antibiotics and cardio cerebrovascular drugs. The technical quality indexes of penicillin industrial salt and 7aca are always at the leading level in China and the first-class level in the world. The company has scientific research and development center, quality inspection center, planning and control center, production, sales, service and other systems and functional departments with advanced technology and equipment and perfect management system, and has a capable, professional, rigorous and efficient management team and dedicated, loyal, United and upward staff team. The company has developed three kinds of new drugs, kailanxin, suzulanxin, cefepime, ceftizole, and dozens of new products, including four kinds of new drugs, ceftizoxime sodium, cefotiam hydrochloride, ceftazidime hydrochloride, etc. Ceftriaxone sterile API is an exclusive product in China, which has won the provincial science and Technology Progress Award and the national key new product certificate; the research achievements of ceftriaxone technology have won the national key new product certificate and the first prize of science and technology progress in the pharmaceutical industry. The leading products of the enterprise are penicillin, cephalosporin raw powder and preparations, which have passed GMP certification of the State Drug Administration; potassium salt of penicillin industry has passed FDA certification of the United States; some APIs and preparations have passed GMP certification of the Ministry of health of South Africa; cefazolin sodium and ceftriaxone sodium raw materials have passed edmf certification of Europe. Harbin Pharmaceutical Group Pharmaceutical General Factory is a key antibiotic production and export base in China. The marketing system consists of nine sales companies, 62 offices in 29 provinces, more than 600 salespeople, and more than 5600 distributors, covering all districts and counties except Hong Kong, Macao and Taiwan. The international trade marketing network covers the markets of the Middle East, Southeast Asia, South America, India, Russia, other countries of the former CIS, Africa, EU, etc. its products are exported to more than 40 countries and regions. In 2010, the most valuable brand evaluation in China, the value of "Harbin Pharmaceutical" brand has reached 16.062 billion yuan, becoming the top of China's pharmaceutical industry and the first brand in Heilongjiang Province. Harbin Pharmaceutical Group Pharmaceutical Factory is a state-level contract abiding and trustworthy unit. Harbin pharmaceutical products enjoy a high reputation in the eyes of customers and consumers for their high quality, efficiency and safety. Harbin Pharmaceutical Group Pharmaceutical General Factory adheres to the enterprise spirit of "being virtuous and hardworking and strong", and always takes the development and expansion of the pharmaceutical industry of the motherland and the benefit of human health as its responsibility. It strives to surpass and strive to build a standardized, modern and international pharmaceutical industry with the most scientific and technological strength, business potential, development tension and cultural charm in China, striving to be a society and a person Class creates greater value.

本文链接: https://brand.waitui.com/2c2f753da.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

广东印发制造业和高新技术企业贷款贴息实施细则,单个企业年度贴息金额最高2000万元

广东省地方金融管理局等六部门近日印发《广东省制造业和高新技术企业贷款贴息实施细则》。其中提出,单个企业年度贴息金额最高2000万元,政策执行期内单笔贷款合同可享受不超过1年贴息,同一笔贷款项目在贴息年度内获得的各级财政贴息资金总额,不得超过贷款利息支付总额。省财政年度贴息对应的贷款总规模,控制在2000亿元以内,三年总规模6000亿元,额度用完即止,达到上限后不再接受新增的银行贴息申请。(财联社)

9分钟前

今年上半年中国电竞产业收入同比增6.1%,直播收入占比最高

8月1日,在2025全球电竞大会上,《2025年1-6月中国电子竞技产业报告》对外发布。报告显示,2025年1月至6月,中国电子竞技产业收入127.61亿元,同比增长6.1%。在电竞产业收入中,截至今年6月,直播收入依然占比最高,为80.38%。赛事、俱乐部和其他收入合计占比19.62%。报告还显示,截至今年6月,中国电子竞技用户规模近4.93亿人,同比增长0.59%。(证券时报)

9分钟前

IMF批准向阿根廷提供20亿美元融资

国际货币基金组织(IMF)理事会7月31日批准向阿根廷提供约20亿美元融资。IMF在声明中说,虽然阿根廷未能实现此前设定的在6月中旬达成净国际储备累计的目标,但“其他关键绩效标准和指示性目标”均已实现,且阿根廷已采取措施朝实现这一目标努力。阿根廷经济部长路易斯·卡普托7月31日确认,IMF这笔资金将于8月4日到账。(央视新闻)

9分钟前

耶鲁大学最新研究:美消费者面临1934年以来最高关税税率

美国耶鲁大学预算实验室最新的研究数据表明,截至7月31日,美国对进口商品征收的平均有效关税税率达18.3%,为1934年以来最高水平。平均有效关税税率并非固定值,而是会随着国家政策、经济形势以及国际贸易环境的变化而调整。该预算实验室认为,关税政策将导致美国2025年和2026年实际国内生产总值增长率每年降低0.5个百分点。同时关税还将导致到2025年底,美国失业率上升0.3个百分点,到2026年底,失业率上升0.7个百分点。 (央视新闻)

9分钟前

韩国计划取消外国游客医美退税政策

韩国的医美产业备受外国游客欢迎,其中不少项目还能享受10%的增值税退税。不过,日前,韩国政府决定,从明年起,取消这一退税政策。记者获悉,为了促进旅游业发展,吸引外国游客来韩接受医美,韩国从2016年4月起,实施了这项退税政策。原本只计划执行一年,但此后多次延长。韩国业内人士担心,取消退税可能导致来韩接受医美的游客减少,还可能促使部分医疗机构与顾客通过现金交易,形成灰色地带。 (央视网)

9分钟前

本页详细列出关于哈药牌的品牌信息,含品牌所属公司介绍,哈药牌所处行业的品牌地位及优势。
咨询